ArticleClinical cancer research : an official journal of the American Association for Cancer Research2005
Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.Oncotarget · 2016Article
- A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Molecular imaging of prostate cancer: PET radiotracers.AJR. American journal of roentgenology · 2012Review
- Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.Cancer research · 2011Article
- Experimental models to study lymphatic and blood vascular metastasis.Journal of surgical oncology · 2011Review
- In vivo imaging of intraprostatic-specific gene transcription by PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011Article
- Molecular imaging of biological gene delivery vehicles for targeted cancer therapy: beyond viral vectors.Nuclear medicine and molecular imaging · 2010Article
- Non-invasive molecular imaging of prostate cancer lymph node metastasis.Trends in molecular medicine · 2009Review
- Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging.Gene therapy · 2008Article
- Down-regulation of androgen-receptor and PSA by phytochemicals.International journal of oncology · 2008Article
- Advances in preclinical investigation of prostate cancer gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2007Review
- Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.European journal of nuclear medicine and molecular imaging · 2007Article
- Saporin as a novel suicide gene in anticancer gene therapy.Cancer gene therapy · 2007Article
- Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.Future oncology (London, England) · 2006Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeA highly augmented, prostate-specific two-step transcriptional amplification (TSTA) method was developed with the ultimate goal of delivering an effective and safe gene-based treatment to prostate cancer patients. Because very limited treatment options are available for recurrent hormone refractory prostate cancer (HRPC), it is imperative to assess whether the prostate-specific antigen (PSA) promoter-based TSTA gene therapy will be functional in HRPC. EXPERIMENTAL
designWe tested the TSTA-driven adenovirus vector on three androgen-dependent and six HRPC models. Real-time gene expression was monitored by both optical imaging and the combined modality of positron emission tomography (PET) and computed tomography.
resultsThe TSTA-driven firefly luciferase expressing adenoviral vector was active in all androgen receptor (AR)-expressing HRPC models, but inactive in AR- and PSA-negative lines. Interestingly, the TSTA-mediated gene expression was induced by hydrocortisone in MDA PCa 2b, a cell line with mutated AR that possesses altered ligand specificity. In animal models, the TSTA-mediated optical signal was more robust in the HRPC than androgen-dependent tumors. In a parallel trend, a TSTA vector that expresses the herpes simplex virus thymidine kinase PET reporter gene also displayed more robust PET signal in the HRPC tumor.
conclusionsThe activity of TSTA system is AR dependent and it recapitulates the functional status of endogenous AR. These data support the conclusion that AR function is activated in HRPC despite castrated levels of androgen. Together with the fact that majority of recurrent prostate cancers express AR and PSA, we foresee that the TSTA approach can be a promising gene therapy strategy for the advanced stages of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.